Medicine

Novartis presents updated data that reinforce the efficacy and safety of Kisqali® (ribociclib) plus letrozole as a first-line option for HR+/HER2- advanced or metastatic breast cancer

Advanced Accelerator Applications S.A. (NASDAQ:AAAP) (AAA or the Company), an international specialist in Molecular Nuclear Medicine (MNM), today announced its financial results for the first quarter ended March 31, 2017

ADMA Biologics, Inc. announced today that its stockholders voted to approve ADMA’s previously announced acquisition of certain assets from Biotest Pharmaceuticals Corporation (BPC), a wholly-owned subsidiary of Biotest AG, at ADMA’s annual meeting of stockholders held on May 25, 2017

PureTech Health's Vedanta Biosciences Granted U.S. Patent Broadly Covering Methods of Treatment with Therapeutics Based on Bacterial Spore Fractions of Microbiota Obtained From Human Donors

JSE Limited listed Aspen Pharmacare (APN), a leading pharmaceutical company in the southern hemisphere, has announced that a memorandum of understanding (“MOU”) has been concluded between Aspen’s Russian business and the Vladivostok Far Eastern Federal University

For the first time, research shows cannabidiol can reduce—and even stop—seizures in a small number of children with severe epilepsy.

Today Bruker announces the launch of its new S8 TIGER™ Series 2, the next-generation Wavelength Dispersive X-Ray Fluorescence (WDXRF) spectrometer.

The compound is under final evaluation with some key pre-clinical studies to confirm efficacy before being progressed into IND enabling trials and thereafter full development studies.

The Canadian Bioceutical Corporation (the “Company” or “BCC”) (CSE:BCC) (OTC:CBICF) today announced that the Company has signed non-binding Letters of Intent (LOI’s) to acquire up to four cannabis enterprises in Arizona and Maryland.

Newron Pharmaceuticals Announces Expansion of STARS Study to Include Patients Under 13 Years of Age

Recent breakthroughs are revolutionising cancer treatment, enabling doctors to personalise chemotherapy for each patient.

Roche provides update on phase III study of TECENTRIQ® (atezolizumab) in people with previously treated advanced bladder cancer

Twenty one of the world’s leading pharmacologists have urged drugs companies and governments to help change the way medication is dosed by signing up to a ‘roadmap for  change’.

Alcon announces EU launch of CyPass® Micro-Stent, a micro invasive glaucoma surgical device, to lower intraocular pressure (IOP) in patients with primary open-angle glaucoma